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S_unmary Wild-type as well as vanrant oestrogen receptor (ER) mRNAs with exon 5 and 7 deleted were
identified in a panel of human breast tumour cell lines by reverse transcriptase-polymerase chain reaction
followed by dideoxynucleotide sequence analysis, and then quantitated by ribonuclease protection analysis. All
cell lines categorised as ER' by ligand-binding analysis expressed both wild-type and variant ER transcripts.
Most cell lines classified as ER- did not express any ER transcript. However, three ER- cell lines (BT-20,
MDA-MB-330 and T47Dco) expressed both wild-type and variant transcripts. A differential pattern of
expression of wild type to variant was seen in both ER' and ER- cell lines, however this pattern was not
paralleled by differences in ligand-binding activity. Breast tumour cell lines previously classified as ER-
expressed significantly lower levels of ER transcripts than did their ER' counterparts. In view of these
findings, as well as earlier reports that the exon 5 deletion ER variant encodes a dominant-positive receptor, it
seems clear that some cell lines are misclassified as ER-, and express both wild-type and variant ER mRNAs.
and that the overexpression of this variant may account, in part, for their oestrogen-independent
phenotype.
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The oestrogen receptor (ER) is a member of the steroid
receptor superfamily, a group of intracellular transcription
factors whose functions are regulated by binding their cog-
nate ligand (Evans et al., 1988). The presence of ER, as
determined by ligand-binding analysis, has been established
as an important prognostic indicator in the treatment of
breast cancer, predicting both a decreased risk of relapse and
improved disease-free survival (Benner et al., 1988). Perhaps
more importantly, ER is a strong predictor of tumour res-
ponsiveness to endocrine therapy (McGuire et al., 1975).
Oestrogen receptor-positive breast tumours are more likely to
respond to hormonal (tamoxifen) therapy, having a response
rate approaching 70%, while ER-negative tumours have a
hormone response rate of only 10% (Edwards et al., 1979). It
has also been demonstrated that steroid receptors, including
ER, possess discrete functional domains for ligand binding,
DNA binding and trans-activation. The DNA-binding
domain of the ER is encoded by exons 2 and 3 of the ER
gene, while the ligand-binding domain is encoded by exons
4-8 (Walter et al., 1985; Kumar et al., 1987; Ponglikitmong-
kol et al., 1988). In addition, numerous subdomains are also
located throughout the ER, including those involved in trans-
cription activation, receptor dimerisation, nuclear localisation
and binding of heat shock proteins (Kumar et al., 1987;
Green and Chambon, 1991).
We have recently identified variant ER mRNA transcripts
containing precise deletions of exon 3, 5 or 7 in breast
tumours classified as ER-negative progesterone receptor
(PgR) positive or ER positive/PgR negative by ligand-
binding analysis (Fuqua et al., 1991, 1992a; McGuire et al.,
1992). We have also observed the exon 5 deletion variant
(A5) ER mRNA in the ER-positive MCF-7 and the ER-
negative BT-20 human breast tumour cell lines (Castles et al.,
1993), while others have identified deletions of exons 4 and 7
in MCF-7 cells (Koehorst et al., 1993; Pfeffer et al., 1993).
Previous studies by our group (Fuqua et al., 1991; 1992a;
Castles et al., 1993) have demonstrated, using a yeast tran-
scriptional assay system, that the protein encoded by the ER
transcript containing a precise deletion of exon 5 acts in a
dominant-positive manner, possessing constitutive transcrip-
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tional regulatory activity. In this same expression system, we
also demonatrated that an exon 7 deletion variant (A7) ER
mRNA was translated into a variant receptor which inter-
fered with the DNA binding and the subsequent trans-acti-
vation capacity of wild-type ER (Fuqua et al., 1992a). In
addition to the MCF-7 and BT-20 cell lines, the T47D breast
tumour cell line also expresses a number of ER mRNA
variants, including frameshift mutations which could poten-
tially encode receptors truncated at the DNA-binding and/or
hormone-binding domains, as well as variants containing
deletions of exon 2, 3 or 7 (Graham et al., 1990; Wang and
Miksicek, 1992; Fuqua et al., 1993).
It is clear from our earlier studies (Fuqua et al., 1992a)
that some variant ER mRNAs are not specific to breast
tumours, but appear to be a somewhat frequent occurrence,
having also been found in non-cancerous uterine tissue. We
report here that variant ER transcripts with exons 5 and 7
deleted are present in a number of human breast tumour cell
lines which had previously been classified as ER positive or
ER negative by ligand-binding analysis. Sequence data from
RT-PCR clones, as well as RNAse protection analysis, has
led to the identification of variant ER mRNAs containing
deletions of exons 5 and/or 7 that are expressed in combina-
tion with the wild-type transcript in a panel of breast tumour
cell lines. Ribonuclease protection assays confirmed these
findings and allowed us to excamine the differences in the level
of expression of these variants with respect to the wild-type
ER transcript in this same panel of breast tumour cell lines.
These studies clearly show that several breast tumour cell
lines classified as ER negative by ligand binding assays do,
indeed, express both wild-type and variant ER mRNA tran-
scripts. However, other breast tumour cell lines categorised
as ER negative do not express any detectable ER mRNA
transcripts.
Materials and methods
Breast cancer cell lines
The BT-20, BT-474, MDA-MB-134, MDA-MB-361, MDA-
MB-435S and MDA-MB-453 cell lines were obatined from
the American Type Culture Collection, Rockville, MD, USA.
The MDA-MB-231, MDA-MB-330, Hs578t, and ZR-75-1cells lines were obtained from Dr CK Osborne, San Antonio,
TX, USA; the MCF-7 cell line was obtained from the late
WL McGuire, San Antonio, TX, USA; and the T47Dco cell
line was obtained from Dr KB Horwitz, Denver, CO, USA.
The MCF-7, ZR-75-1, BT-474, BT-20, T47Dco, MDA-MB-
231, MDA-MB-330 and Hs578t cell lines were maintained in
Dulbecco's modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Gibco-BRL, Gaithers-
burg, MD, USA), basic minimal essential (BME) amino
acids, MEM non-essential amino acids, L-glutamnlne, penicil-
lin-streptomycin and procine insulin (10-' M) (Sigma, St
Louis, MO, USA). The MDA-MB-134 and MDA-MB-361
cell lines were maintained in DMEM as above, but supple-
mented with 20% FBS. The MDA-MB-435S and MDA-MB-
453 cell lines were maintained in L-15 medium supplemented
with 10% FBS with and without 10-' M insulin respectively.
Stock cells were grown in 75 cm2 culture flasks in a
humidified atmosphere of 5% carbon dioxide and 95% air at
a constant temperature of 3TC. Cells for RT-PCR as well as
RNAse protection analysis were harvested from 150 cm2 cul-
ture flasks at 75% confluence using a solution of 10 mM
EDTA in PBS, pelleted at >600 g, snap frozen in liquid
nitrogen and stored at - 70'C until RNA could be extracted.
RNA isolation, RT-PCR amplification, cloning and
sequencing
Total cellular RNA was isolated in a single step procedure
(Chomczynski and Sacchi, 1987) by homogenisation of
frozen pellets using RNazol B (Cinna-Biotecx Laboratories,
Houston, TX, USA) according to the manufacturer's instruc-
tions. The concentration and integrity of RNA were deter-
mined spectrophotometrically at an absorbance of 260 nm
and by agarose gel electrophoresis. Reverse transcriptase-
polymerase chain reaction was used to amplify regions of the
ER mRNA isolated from MCF-7, MDA-MB-361, MDA-
MB-330 and MDA-MB-231 breast cancer cell lines as des-
cribed previously (Castles et al., 1993). To amplify across the
E region of the ER mRNA (exons 4-8) as described by
Ponglikitmongkol et al. (1988), two pairs of oligonucleotide
primers, HblO/Hbll and Hbl8/ERY6, which correspond to
nucleotide sequences 1142-1162 and 1561-1580 and 1542-
1561 and 2012-2031 respectively, of the ER cDNA (Greene
et al., 1986) were used. To ensure that no alterations were
contained in the DNA-binding domain of the ER mRNA
(exons 2 and 3), another pair of primers, ERY4/ERY2,
which correspond to nucleotide sequences 731-750 and
1296-1315, was used to amplify and sequence this region. In
addition, the primer pair AB6/AB2, corresponding to
nucleotides 281-300 and 870-889, was used to amplify the
A/B region of the ER mRNA (exons 1 and 2) in these cell
lines. To the 5' end of each primer, two additional nucleo-
tides were added to facilitate cutting at an introduced EcoRI
restnction site. Reverse transcriptase-polymerase chain re-
action products were gel purified and then cloned into
pGEM7zf(+) vectors (Promega, Madison, WI, USA).
Double-stranded plasmid DNAs containing the cDNA
inserts were alkali denatured (Chen and Seeburg, 1985) and
both strands were sequenced (Sequenase version 2.0, United
States Biochemicals, Cleveland, OH, USA) using SP6 and T7
promoter primers (Sanger et al., 1977), and then compared
with those sequences reported in the Genetic sequence Data
Bank (EMBL/GenBank).
RNAse protection analysis
Thirty micrograms of total RNA from each ER-positive cell
line (MCF-7, ZR-75-1, MDA-MB-134 and MDA-MB-361)
and 60 pg of RNA from each ER-negative cell line (BT-20,
T47Dco, BT474, MDA-MB-330, MDA-MB-435S, MDA-
MB-453, MDA-MB-231 and Hs578t) was hybridised to a
32P-labelled antisense cRNA ER variant probe lacking either
exon 5 (A5) or exon 7 (A7). A [nP1}labelled antisense cRNA
probe generated from the cDNA for the constitutively ex-
pressed 36B4 gene product was utilised as a loading control.
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The A5 probe was generated by transcribing the ER variant
cDNA clone containing portions of exons 4 and 6 (nucleo-
tides 1142-1580) (Castles et al., 1993), but with exon 5
(nucleotides 1389-1527) deleted. The A7 probe was generat-
ed using a cDNA clone containing portions of exons 6 and 8
(nucleotides 1542-2031) but with exon 7 (nucleotides 1662-
1845) deleted. Radiolabelled variant ER antisense cRNA
probe was generated using a Riboprobe Gemini II Core
System (Promega) and purified by polyacrylamide gel electro-
phoresis. Hybridisation of 1 x 106c.p.m. of labelled probe
with sample RNA and subsequent digestion with RNAses A
and T, were carried out using an RPA kit II (Ambion,
Austin, TX, USA). The samples were heated at 85°C for
5 mi, loaded onto a 6% polyacrylamide/8 M urea gel and
ekctrophoresed at 1200V for 4 h. Gels were dried and expos-
ed to Kodak XAR film at -70°C for 18-48h.
The numbers generated by densitometric analysis were cor-
rected to account for the molar differences in size between
the fully protected variant fragments and the partially pro-
tected wild-type fragment. The overall amount of radio-
activity (probe) bound to the partially protected wild-type
fragment identified in Figure 3 was approximately 20% less
than that bound to the full-length protected fragment of the
A5 variant transcript. Similarly, the numbers generated by
densitometric analysis of the A7 assays were corrected to
account for the molar differences in size between the two
protected fragments. The partially protected wild-type frag-
ment contained approximately 40% less radioactivity than
the full-length protected fragment of the A7 vanrant tran-
script.
Res
RT-PCR amplification, cloning andsequence analysis
Total cellular RNA from the ER-positive MCF-7 and MDA-
MB-361 cell lines and the ER-negative MDA-MB-330 and
MDA-MB-231 cell lines was reverse transcribed and cDNA
fragments from nucleotides 1142-1580 of the ER mRNA
amplified by PCR using the primers HBIO and HB11.
Amplified products were then separated on a 5% polyac-
rylamide gel. Similar to what has been previously demon-
strated in some primary breast tumours (Fuqua et al., 1991),
all of these breast tumour cell lines except the MDA-MB-231
line expressed two amplified products: a larger 438 bp prod-
uct which corresponds in size to the expected wild-type ER
product and a smaller 300 bp variant band (Figure la).
Dideoxynucleotide sequence analysis of the larger fragment
from MCF-7, MDA-MB-361, BT-20 and MDA-MB-330 cells
confirmed sequences established for the human ER (Pong-
likitmongkol et al., 1988), while the smaller variant fragment
was found to contain wild-type sequences for exons 4 and 6
with exon 5 deleted (Castles et al., 1993).
Reverse transcriptase-polymerase chain reaction amplifi-
cation oftotal RNA from the four cell lines mentioned above
was also performed using the primers HB18 and ERY6 to
generate cDNA fragments from nucleotides 1553-2042 of
the ER mRNA (Figure lb). The MCF-7, MDA-MB-361 and
MDA-MB-330 cell lines expressed two amplified products: a
larger 489 bp product which correlated with the expected size
of the wild-type ER product and a smaller 305 bp variant
transcript. Clones from each of these cell lines containing the
489 bp product were sequenced and shown to correspond to
the wild-type sequence for the ER. A representative sequence
from the MDA-MB-330 cell line is shown in Figure 2.
Sequence analysis of the cloned 305 bp product from MDA-
MB-330 (Figure 2) as well as other cell lines (MCF-7, BT-20
and MDA-MB-361) revealed wild-type sequences for exons 6
and 8 with exon 7 deleted. Complete sequence analysis of
both the A5 and A7 variants indicates that these deletions
correspond to known intron/exon boundaries. The MDA-
MB-231 cell line failed to express any ER mRNA trans-
cripts.ER vrin'-hum. be Bur cml Ems
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Fuwe I RT-PCR analysis of ER mRNA transcripts from human breast tumour cell lines. Total RNA from MCF-7,
MDA-MB-361, MDA-MB-330 and MDA-MB-231 human breast tumour cell lines was reverse transcribed and amplified using the
primer sets HblO-Hbl1 (a) and Hbl8-ERY6 (b). Amplified products were run on a 5% polyacrylamide geL stained with ethidium
bromide and photographed. Arrows indicate exon deletion variant or wild-type ER cDNA generated from each cell line. All cell
lines, with the exception of the MDA-MB-231 cell line, expressed A5 (300bp) (a), A7 (305 bp) (b) and wild-type ER transcripts
(438 and 489 bp respectively), as shown by the presence ofamplified products. The molecular weight marker used in this gel is Phi
DNA digested with HaelH. The numbers inside the cDNA box correspond to the exons of the ER cDNA.
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Fugwe 2 Sequence analysis of ER mRNA variants lacking exon 7 from BT-20 hunan breast cancer cells. Total RNA from the
MCF-7, BT-20, MDA-MB-361, MDA-MB-330 and MDA-MB-231 cell lnes was reverse transcribed and the cDNA amplified by
PCR. Variant and wild-type PCR-derived cDNAs were cloned into pGEM-7zf(+) vectors and subjected to dideoxysequence
analysis. Arrows indicate exon boundaries. The MCF-7, MDA-MB-361, MDA-MB-330 and BT-20 cell lines expressed the
wild-type ER mRNA coexpressed with the exon 5 (not shown) and exon 7 deletion variants.
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Figure 3 RNAse protection analysis of ER mRl
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Detection and quantitation ofER mRNA transcripts in a panel
ofbreast tumour cell lines using RNAseprotection analysis
In order to determine if the A5 and A7 ER mRNA variants
are expressed in a panel of human breast tumour cell lines
and to compare the relative level of expression of these
variants with that of the wild-type ER, RNAse protection
analysis was performed using antisense cRNA probes gener-
ated from the cDNAs containing the exon deletions as de-
rExon scribed above. A fully protected 300 nt fragment correspond-
probe ing to the A5 variant and a partially protected 246 nt frag-
Exon 5 ment corresponding to the wild-type ER mRNA were
deletion detected in the ER-positive MCF-7, ZR-75-1, MDA-MB-361
Wild-type and MDA-MB-134 and the ER-negative MDA-MB-330, BT-
ER 474, T47Dco and BT-20 cell lines (Figure 3). The true ER-
negative MDA-MB-435S, MDA-MB-453, MDA-MB-231
and Hs578t cell lines did not express any ER transcripts. As
seen in Figure 4, each cell line which expressed a A5 variant
ER transcript coexpressed some amount ofwild-type message
as well, although the expression ratio of variant to wild-type
transcript differed among the various cell lines examined. In
addition to the wild-type and A5 transcripts, the MDA-MB-
36B4 loading 231 cells also contained a novel partially protected fragment
control at approximately 287 nt. The exact make-up of this fragment
has not been completely determined at present. In order to
see clearly wild-type and variant transcripts in the ER-nega-
NA from a panel tive cell lines (e.g. BT-20 and MDA-MB-330), longer film
exon 5 deletion exposure times were used. This resulted in all transcripts
k from these cell from the ER-positive cell lines being overexposed in Figure 3.
probe prepared Densitometric analysis was, however, performed on films that
)n 5 deleted. The weentorxpsd
binding analysis) A fully protected 306 nt fragment corresponding to the A7 s,iexpressed both variant and a partially protected 185 nt fragment correspond-
nt) and the par- ing to the wild-type and other ER mRNA transcripts (e.g.
(245 nt). No ER A5) were detected in the ER-positive MCF-7, ZR-75-1,
MDA-MB-435S, MDA-MB-361 and MDA-MB-134 cell lines (Figure 4).
lines. The pre- While many of the ER-negative cell lines (MDA-MB-435S,
xll lines examin- MDA-MB-453, MDA-MB-231 and Hs578t) failed to express
4A digested with any detectable levels of ER mRNA, some of the cell lines
NA was used to previously reported as ER negative (based on ligand-binding
Z ER+ ER-
U) 0 Lfl cn
o- 0 4 C") N~
.
r- 0 70
CD U et °
< O 0 N ina
7-
nt
404
309
Exon 7 probe _
Exon 7 deletion _
Wild-type ER _
36B4 loading
control
242
217
201
180
Figure 4 RNAse protection analysis of ER mRNA from a panel of human breast cancer cell lines using the exon 7 deletion
antisense cRNA. Fifty micrograms of total RNA from these cell lines was hybridised with an antisense cRNA probe prepared from
a PCR-derived variant ER cDNA with exon 7 deleted. The ER-positive MCF-7, ZR-75-1, MDA-MB-361 and MDA-MB-134 cell
lines as well as the ER-negative (by ligand-binding analysis) BT-474, T47Dco, MDA-MB-330 and BT-20 cells expressed both a
fully protected A7 transcript (305 nt fragment) and a partially protected wild-type fragment (184 nt). The molecular weight
standard is pBR322 DNA digested with MspI. The 36B4 cRNA was used to monitor RNA loading.
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Figwe 5 Composite densitometnrc analysis of RNAse protection
assays. Following densitometric scanning of RPA autoradio-
graphs, the relative expression of wild-type and vanrant ER
mRNA species was compiled for the panel of human breast
cancer cell lines. The predominant ER transcript varied among
the cell lines, with some cell lines (e.g. MCF-7) expressing more
wild-type ER mRNA and other cell lines (e.g. MDA-MB-361)
expressing more A5 vanant. The A7 variant transcript was con-
stitutively expressed at low levels in all cell lines except the
MDA-MB-134 and BT-20 cell lines.
analysis) did express both A7 variant and wild-type ER
transcripts. These include the MDA-MB-330, T47Dco, BT-20
and BT-474 cell lines. A complete densitometric analysis of
each RNAse protection assay is graphically represented as
the combined expresson of both the AS and A7 variants and
the wild-type ER mRNA transcripts (Figure 5). Densitome-
tric analysis of autoradiographs demonstrated that the A7
vanant transcript appeared to be less abundant than either
the A5 variant or the wild-type transcript in cell lines express-
ing detectable levels of ER mRNA. The one exception to this
was the BT-20 cell line, which expressed slightly more A7
variant than wild-type.
Further analysis revealed that differences in the expression
levels of the ER vanrants among the cell lines were more
pronounced for the ratio of the A5 variant to wild-type
(Figure 5) than for A7 to wild type. For example, in the
MCF-7 cell line (Figure 5, Table I), the wild-type ER mRNA
accounted for over 57% of the ER transcripts, while the A5
variant accounted for 39% and the A7 variant less than 4%
of the total ER mRNA transcripts. In the weakly ER-
positive MDA-MB-361 cells, the A5 variant accounted for
51% of the ER mRNA transcripts, the wild-type accounted
for 34% and the A7 vanrant 17% of the total ER mRNA
species (Table I). Conversely, in BT-20 cells, which are
classified as ER negative based on ligand-binding analysis,
the A5 variant transcript made up over 68% of the total ER
mRNA transcripts, while the A7 variant accounted for 24%
and the wild-type approximately 8% of the total ER tran-
scripts. Like the BT-20 cells the MDA-MB-134 cell line was
the only ER-positive cell line that expressed elevated levels of
the A7 transcript (25%). This assay methodology (RNAse
protection analysis) generates different molar ratios (different
sized radiolabelled protected fragments) between the fully
protected variant and the partially protected wild-type tran-
script. Since the smaller protected fragment represents less
radioactive RNA than the larger variant fragment, true ex-
pression differences between variant and wild-type transcripts
are not clearly evident upon visual inspection of autoradio-
graphs. Thus, for accurate measurement of transcript ratios,
mathematical manipulations were performed on the densito-
metric data to correct for the molar differences in fragment
size. In addition, since the smaller protected fragments in
both A5 and A7 assays contain wild-type ER mRNA as well
as one of the vanrant transcripts (depending on which variant
probe is used), further adjustments in the expression levels
Table I Average per cent composition of total ER mRNA from a
panel of breast cancer cell lines
Cell line WiI-tpe (Go A5 variant (%) A7 variant (%)
MCF-7(M) 57 39 4
ZR-75-1 41 47 12
MDA-MB-361 41 51 7
MDA-MB-134 34 41 25
BT-474 41 44 15
T47Dco 39 47 14
BT-20 8 68 24
MDA-MB-330 27 58 15
MDA-MB-435S - - -
MDA-MB 453 - - -
MDA-MB-231 - - -
Hs578t - - -
Note that in some cell lines, such as MCF-7. the wild type was the
predominant transcript, while in other cell lines, such as
MDA-MB-361 and BT-20, the A5 deletion variant was the
predominant transcript. Samples were normalised to the loading
control. These data are based on the mean of three assays ± s.e.
were made by subtracting A5 or A7 levels from the smaller
fragment in the parallel assay with the other probe.
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We report here that a number of human breast tumour cell
lines express ER mRNA variants which contain precise dele-
tions of exons S and/or 7. Several ER-positive cell lines as
well as some ER-negative cell lines were found to contain
varying levels of both wild-type and the two ER variant
transcripts. These cell lines include the ER-positive MCF-7,
ZR-75-1, MDA-MB-134 and MDA-MB-361 as well as the
ER-negative BT-20, MDA-MB-330, BT474 and T47Dco cell
lines. Some ER-negative cell lines, including MDA-MB-231,
MDA-MB-435s, MDA-MB-453 and Hs578t, failed to express
any detectable levels of ER and mRNA.
We have previously identified and characterised the A5
variant ER transcript in the ER-positive MCF-7 and ER-
negative BT-20 cell lines (Fuqua et al., 1991; Castles et al.,
1993). This variant transcript encodes a transcriptionally
active, dominant-positive variant ER protein. According to
our RNAse protection analyses, this variant transcript is the
predominant ER mRNA species expressed in the ER-positive
MDA-MB-361, MDA-MB-134 and ER-negative BT-20 and
MDA-MB-330 cell lines, accounting for 51%, 68%, 41% and
58%, respectively, of the total ER mRNA. We have also
previously identified (Fuqua et al., 1992a) in breast tumour
specimens a A7 ER mRNA variant that encodes a dominant-
negative receptor which interferes with the ability of the
wild-type receptor to activate gene transcnption in a yeast
reporter assay system. This particular variant ER transcript,
along with other variants lacking exons 2 or 3, has been
previously identified in the ER-positive T47D cell line (Wang
and Miksicek, 1992), as well as in conjunction with a deletion
of exon 4 in MCF-7 cells (Koehorst et al., 1993).
The coexpression of ER mRNA variants with the wild
type is in agreement with earlier reports examining breast
tumour specimens (Fuqua et al., 1991, 1992a; Zhang et al.,
1993) and the T47D, ZR-75-1, and MCF-7 cell lines (Wang
and Miksicek, 1992; Koehorst et al., 1993). However, based
on RNAse protection analysis, the ratio of expression of the
A5 and A7 mRNA vanrants to each other as well as to the
wild-type ER transcript differed among the cell lines examin-
ed. This can also be observed in panels of ER-positive/PgR-
positive and ER-positive/PgR-negative breast tumours (SAW
Fuqua, unpublished data). In cell lines such as the ER-
positive MCF-7 cell line (Figure 5, Table I), the wild-type ER
transcript accounted for over 57% of the total ER trans-
cripts, while the A5 transcript made up 39% and the A7
variant less than 4%. In the ER-positive MDA-MB-134 cell
line, the A5 ER variant accounted for 41% of the ER
mRNA transcripts, with the wild-type making up 34% and
978the A7 variant 25%. In the BT-474 cell line, the A5 variant
and wild-type ER mRNA transcripts were expressed at
nearly equivalent levels, while only minimal levels of the A7
transcript were expressed. This cell line, classified as ER
negative by Lasfargues et al. (1978) based on ligand-binding
analysis, constitutively expresses high levels of PgR. How-
ever, a recent report by Hall et al. (1990) indicates that this
cell line does, in fact, express an ER transcript.
In the T47Dco cell line, which is also ER negative/PgR
positive (Horwitz, 1982), the wild-type message is not the
predominant ER transcript, making up only 39% of the total
amount of ER mRNA transcripts, with the A5 variant
accounting for 47%. However, in this cell line, ER tran-
scripts are expressed at levels well below the ER-positive cell
lines. In the ER-negative BT-20 cell line, the A5 variant made
up over 68% of the ER mRNA transcripts, with the wild-
type accounting for only 8% of the detectable ER tran-
scripts. This was the only cell line examined which expressed
levels of the A7 variant (24%) which were equivalent or
slightly greater than the levels of the wild-type (8%) ER
transcript. However, in all of these cell lines there did not
appear to be a significant correlation between the level of
expression of the A5 variant ER mRNA transcripts and
oestrogen-binding activity as measured by ligand-binding
analysis as demonstrated by the T47Dco (ER-) and MCF-7
(ER') cell lines, which both express wild type as the
predominant ER transcript. Conversely, two ER-positive cell
lines (MDA-MB-134 and MDA-MB-361) and two ER-nega-
tive cell lines (BT-20 and MDA-MB-330) expressed predom-
inantly the AS ER variant transcript. All cell lines expressing
ER transcripts but classified as ER negative by ligand-
binding analysis expressed significantly lower levels of all ER
transcripts than did their ER-positive counterparts. It should
again be pointed out that the expression ratios of the ER
mRNA variants to each other and to the wild-type tran-
script, as well as the per cent expression of each ER mRNA
species, were based solely upon the RNAse protection ana-
lysis. These results differ somewhat from the recent observa-
tions of Zhang et al. (1993), who used this same technique to
examine the expression of the A5 variant transcript in the
MCF-7 and ZR-75-1 breast tumour cell lines. While the
expression ratios of A5 to wild type were similar for MCF-7
cells in both studies, the ZR-75-1 cells in our study had an
expression ratio approaching 1:1; in contrast Zhang et al.
reported a ratio of 0.5:1. These differences may be the result
of inter-assay variation. However, we have recently reported
that different stocks of the MCF-7 cell line express con-
siderably different ratios of A5 to wild type transcripts, and
that the mitogenic effects of 17p-oestradiol in the various
MCF-7 stocks is significantly correlated with the expression
ratio of wild-type to variant ER mRNA (Klotz et al., 1994).
Thus, the differential expression of variant to wild-type ER
mRNA may be related to the oestrogen responsiveness of the
cells. It is apparent that the AS variant is expressed at higher
levels than the A7 variant in all cell lines examined, suggest-
ing that these two deletions do not reside on the same ER
mRNA transcript, but may be the result of alternative splic-
ing and the formation of separate transcripts.
Although we have identified A5 and A7 ER mRNA vari-
ants in several breast tumour cell lines, as yet there is no
clear evidence that ER variant proteins serve a specific func-
tion in either normal or cancerous cells in vivo. We have,
however, identified in MCF-7 and BT-20 breast tumour cells
immunoreactive proteins corresponding in size to the wild-
type ER (65 kDa) and the A5 ER variant (42 kDa (Castles et
al., 1993). In the current studies we have not attempted to
quantitate the protein levels since such studies would involve
immunoprecipitation and Western blot analysis using the
H226 ER monoclonal antibody, whose production has been
ER --imi h." k n ow cd km
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discontinued by our supplier Abbott Laboratories (Abbott,
IL, USA). In a yeast expression system, the A5 ER variant
protein acts in a dominant-positive manner to activate consti-
tutively transcription of an ER-regulated gene construct,
while the A7 ER variant exhibits dominant-negative activity,
interfenng with the ability of the wild-type ER to initiate
gene transcription (Fuqua et al., 1991, 1992a; Castles et al.,
1993). Both the A5 and A7 variant proteins when expressed
in yeast are truncated forms of the ER, with each variant
missing a portion of the hormone-binding domain as well as
the dimerisation and AF-2 domains located in the E region
of the ER (Fawell et al., 1990). Since the A5 variant is the
predominant ER mRNA isoform in the BT-20 cell line
(Castles et al., 1993), which is ER negative by ligand-binding
analysis, and since Fuqua et al. (1992b) have shown that,
when expressed in MCF-7 cells, this variant is able to confer
hormone independence and tamoxifen resistance, it is possi-
ble that expression of this variant may contribute to the
hormone indepenent proliferation of the BT-20 and MDA-
MB-330 cells.
The A7 ER variant has been shown, by our group, to act
in a dominant-negative manner, apparently dimerising with
the wild-type receptor to form an inactive heterodiner
(Fuqua et al., 1992a). This variant is expressed at higher
levels in the MDA-MB-134 cell line than in other ER-
positive cell lines. It is interesting to note that this cell line,
although ER positive by ligand binding, is not induced to
express PgR in response to oestrogen stimulation (data not
shown) (Reiner et al., 1986). In addition, this cell line also
expresses, as detrmined by RNAse protection analysis, a
partially protected fragment of intermediate size between the
wild-type and the A5 transcript. The exact nature of this
partially protected fragment has not been fully characterised
so far. Considering the high level ofA7 expression in this cell
line, it is tempting to speculate that elevated levels of this
variant may play a role in the lack of PgR induction by
oestradiol, although oestrogen-induced proliferation is not
inhibited in these cells. The low-level constitutive expression
of PgR in these cells might then be due to.gene activation by
the constitutively active truncated A5 ER variant. This
variant would not be expected to dimerise with the A7
variant since it is truncated and missing its dimerisation
domain. Further studies to characterise these variant ERs,
such as analysis of DNA-binding properties, will be needed
to determine the true clinical significnce of such variants.
The coexpression of the A5 and A7 variant transcripts with
the wild-type message in both ER-positive and ER-negative
breast cancer cell lines may simply be a reflection of the
cancerous state of these cells. However, this is probable not
the case since these and other ER mRNA variants have been
identified in normal/non-malignant tissues such as the uterus
and brain (Koehorst et al., 1993). Thus, they appear to be
naturally occurring splicing variants which may play a role in
the development or normal function of some oestrogen-
responsive tissues. It is possible that the overexpression of
such variants in relation to the wild-type ER might be related
to the development of a malignant phenotype or to hormone
resistance m some breast tumours. Given the potential
biological action of these ER variants, it is probably that
their differential expression may be an important factor in
modulating the overall oestrogen responsiveness of various
tissues as well as the expression of oestrogen responsive
genes.
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